A5071634938- Cervical Cancer and HPV Research
- Global Cancer Incidence and Screening
- COVID-19 and healthcare impacts
- Molecular Biology Techniques and Applications
- Ethics in Clinical Research
- Hepatitis B Virus Studies
Erasmus MC
2022-2025
Population-level estimates in timeframes for reaching cervical cancer (CC) elimination (ie, <4 cases per 100,000 women) the United States may mask potential disparities achieving among sub-populations. We used three independent Cancer Intervention and Surveillance Modeling Network (CISNET) models to estimate differences time CC across seven strata of correlated screening human papillomavirus vaccination uptake, based on national survey data. Compared average population, was achieved ≥22...
ObjectivesIn Ontario, Canada, the first cohorts who were offered school-based human papillomavirus (HPV) vaccination are now eligible for cervical screening. We determined which screening strategies these populations would result in optimal harms-benefits ratios of screening.MethodsWe used hybrid microsimulation model STDSIM- MISCAN-Cervix to determine harms and cancers prevented 309 different primary HPV strategies, varying by ages triage methods. In addition, we performed an unstratified...
We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due heterogeneity in their history and test modality. used three CC models project the short- long-term health impacts assuming an underlying frequency (i.e., 1, 3, 5, or 10 yearly) under alternative COVID-19-related disruption scenarios 1-, 2-, 5-year delay) versus no delay context of both cytology-based human papillomavirus (HPV)-based screening. Models projected a...
ABSTRACT Background We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due heterogeneity in their history and test modality. Methods used three CC models project the short- long-term health impacts assuming an underlying frequency (i.e., 1, 3, 5, or 10 yearly) under alternative COVID-19-related disruption scenarios 1-, 2- 5-year delay) versus no delay, context of both cytology-based HPV-based screening. Results Models...